Sanofi Starts Construction on New Insulin Plant at Its Frankfurt BioCampus
Sanofi broke ground on October 19 on a new insulin manufacturing facility at its Frankfurt BioCampus in Germany, one of its largest combined research and manufacturing sites. The company says the plant will bring a new generation of insulin production to the site and secure long-term global supply.
Our summary of an article from Sanofi (company press release). Read the original at Sanofi (company press release)
What It Means
Insulin is a high-volume product, and building new capacity inside a long-running integrated campus means tying into existing utilities and quality systems without disrupting the lines already running. Brownfield work like this tests how well project teams can phase construction, commissioning and validation around live operations.
Read the original at Sanofi (company press release).
